Description des conditions d'utilisation en vie réèlle d'ADTRALZA chez les patients atteints de dermatite atopique à partir d'une base de données secondaire.

Objectif(s) de la recherche et intérêt pour la santé publique

Finalité de l'étude

Objectifs poursuivis

Domaines médicaux investigués

Bénéfices attendus

DUPIXENT® (starting 2018), and more recently ADTRALZA® (starting 2022) are both available biologics with identical reimbursed indications in France in AD: “treatment of moderate to severe atopic dermatitis in adults who require systemic treatment, in case of failure, intolerance or contraindication to cyclosporin”. However, there is no data on real-world compliance of prescription to the reimbursed indication in France for ADTRALZA®. The MOVE study on DUPIXENT® only included data collected between 2019 and 2021 in a limited subset of the French population (n=594). Therefore, this study aims to produce real-world data on this topic on a larger sample of the French population.

Primary objective:
- Describe AD systemic treatments history before initiation of ADTRALZA® or DUPIXENT®, overall and according to prior use of other biologics and Janus Kinase Inhibitors (JAKi).

This is a retrospective descriptive study of patients treated with DUPIXENT® and/or ADTRALZA® for AD identified in the French IQVIA LRx pharmacy claims database, which will cover the period between February 1st, 2018 to July 31st, 2024.